Healthcare Wrap Week 6: Rhythm rockets, Neuren slides, and capital raises reshape the field

• Rhythm Biosciences (ASX:RHY) surged on a manufacturing deal that investors see as a practical step towards selling its bowel cancer test at scale
• Osteopore (ASX:OSX) slid despite confirming a $5m convertible note drawdown, a funding type that can worry shareholders about future dilution
• Neuren Pharmaceuticals (ASX:NEU) fell as investors weighed mixed rare-disease updates, including an EU setback for a partnered Rett syndrome drug
• Cyclopharm (ASX:CYC) raised fresh equity to expand Technegas in the US after record revenue, but the share price still dropped sharply on the week